Vaccinex (VCNX)

Executive Summary

Vaccinex is a clinical-stage biotechnology company focused on developing pepinemab, a monoclonal antibody targeting SEMA4D, for oncology and neurodegenerative diseases. The company's pipeline includes multiple ongoing trials, with lead programs in Alzheimer's disease (Phase 1/2 completed), Huntington's disease (Phase 2 completed), and several oncology indications including metastatic pancreatic adenocarcinoma (Phase 1/2 active), HER2-positive breast cancer (Phase 1 recruiting), and head and neck squamous cell carcinoma (Phase 1 recruiting). Vaccinex's proprietary ACTIVMAb® platform enables discovery of antibodies against difficult multi-pass membrane proteins. With a market cap around $2.8M, the company faces significant financial constraints typical of early-stage biotechs. Key upcoming catalysts include interim data from ongoing oncology trials and potential partnership opportunities to advance pepinemab development. The company's near-term viability hinges on successful clinical data readouts and securing additional funding or strategic collaborations.

Upcoming Catalysts (preview)

• H2 2026Interim efficacy/safety data from Phase 1/2 trial of avelumab + pepinemab in metastatic pancreatic adenocarcinoma (NCT05102721)15% success
• 2026Interim data from Phase 1 trial of pepinemab + ipilimumab + nivolumab in head and neck squamous cell carcinoma (NCT03690986)20% success
• TBDPotential partnership or licensing deal for pepinemab in neurodegenerative or oncology indications10% success